Sera Prognostics, Inc. (NasdaqGM: SERA)
Health Care · Biotechnology · US
$2.18
+1.87% today · -18.9% 1Y
Sera Prognostics, Inc. (NasdaqGM: SERA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $84.42M and employs 72 people.
Over the last twelve months the share price has lost 18.9%, trading between 1.56 and 3.95.
Tweenvest scores Sera Prognostics, Inc. across four factors: quality 29/100, value 40/100. Its strongest factor is value.
SERA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $84.42M
- Revenue (TTM)
- $70.00K
- P/E
- —
- EPS
- -0.66
- Dividend yield
- —
- Beta (5Y)
- 0.98
- 52-week high
- $3.95
- 52-week low
- $1.56
- Avg volume (3M)
- —
- Shares outstanding
- 39.45M
- Employees
- 72
- Next earnings
- —
About Sera Prognostics, Inc.
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
- ISIN
- US81749D1072
- Founded
- 2008
- Listed since
- Jul 15, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.